Weight gain is a known risk factor for the development of type 2 diabetes and even modest weight reduction can reduce the risk of developing diabetes, so controlling body weight is an important public health goal in the fight against diabetes and its comorbidities. Weight reduction is also a cornerstone of diabetes management, improving glycaemic control and reducing other risk factors associated with this disease. Pharmacotherapies such as sibutramine contribute to the management of type 2 diabetes in overweight and obese patients. International Journal of Obesity (2001) 
Overview
Obesity is becoming increasingly common and is recognised as a major public health problem worldwide. 1 There is also growing evidence that obesity, and in particular central adiposity, has an important impact on predisposing metabolic risk factors for coronary heart disease such as hypertension, dyslipidaemia, glucose intolerance and diabetes. Reversal of these obesity-associated metabolic abnormalities is, therefore, one of the most important targets in the clinical management of patients prone to diabetes and coronary heart disease.
Type 2 diabetes
Public perceptions regarding the risks and health problems associated with obesity show that there is high awareness of the link between being overweight and the development of cardiovascular diseases. A Gallup poll conducted in the USA in 1996 revealed, however, that the public -and therefore many overweight patients -fail to appreciate that obesity and diabetes are closely linked. 2 Yet there is a wealth of evidence to show that weight gain is a risk factor for the development of type 2 diabetes. 3, 4 The relative risk of developing type 2 diabetes increases as body mass index (BMI) increases. Even individuals with a BMI of 25 -30 kg=m 2 , who might be considered overweight rather than clinically obese, have a higher risk of developing type 2 diabetes than otherwise healthy individuals of normal weight and detailed longitudinal studies show that the risk increases even within the normal weight range as the BMI increases from about 21.0.
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A particular risk factor marker for diabetes in overweight individuals is central obesity. Waist circumference reflects visceral fat and is highly predictive of an increased level of risk for type 2 diabetes. The seminal studies of Ohlson et al project that overweight individuals with a high waist : hip ratio have a 15% probability of developing type 2 diabetes over a period of 13.5 y. 3 There is a synergy between the diabetic risk of increases in the waist : hip ratio and increases in BMI.
It also appears that the age of onset of obesity affects the risks for type 2 diabetes. A woman who has a high BMI at 18 y of age and who continues to gain weight in adulthood has nearly an 80-fold increased risk of developing type 2 diabetes. 5 When in addition to these anthropometric factors, there exists a familial history of diabetes or a personal history of gestational diabetes, the risk is likely to increase further. Type 2 diabetes ranks highly when compared with other clinical conditions for which obesity is a known risk factor or comorbidity. The proportion of type 2 diabetes attributable to obesity has been estimated to be 61% in one study, whereas with hypertension and coronary heart disease only 17% can be attributed directly to obesity. 6 The Hoorn study 7 and other estimates suggest that the prevalence of type 2 diabetes is as great as 3.6% of the older population (50 -74 y), while a further 4.8% were found on screening to have unrecognised diabetes, and a further 10.3% were likely to have impaired glucose tolerance (IGT) -a prediabetic state that may develop into clinically recognisable diabetes.
Weight loss reduces risk of type 2 diabetes
Preventative strategies designed to tackle excess weight can have an impact on the risk for diabetes. Even modest weight loss (ie 5 -10% body weight reduction) can reduce the risk of type 2 diabetes by as much as 50% (see Figure 1) . 8 These benefits of weight loss are seen regardless of whether the weight is lost through diet, exercise or a combination of the two.
Furthermore, if weight loss can be sustained, there may be further reductions in the relative risk of type 2 diabetes. A study by Moore et al, looking at weight loss maintained over two consecutive 8 y periods, noted that individuals who sustained weight loss (3.6 -6.8 kg) could enjoy a 33% reduction in the risk of diabetes. 9 Greater weight losses ( > 6.8 kg) maintained for the same time period gave a 51% reduction in diabetes risk.
A recent report from the Finnish Diabetes Prevention Study revealed that lifestyle intervention can lead to a substantial reduction (up to 58%) in the onset of type 2 diabetes in high-risk subjects with a minimal weight reduction. 10 
Difficulties of weight loss in diabetic patients
Once a patient has type 2 diabetes, it remains a desirable, primary management goal to achieve weight loss in order to improve glycaemic control. However, patients with type 2 diabetes find it more difficult to lose weight than obese individuals who do not have diabetes. A study by Wing et al, looking at weight loss in obese diabetic patients compared with their overweight non-diabetic spouses, showed that significantly less weight was lost by the diabetic subgroup during a diet and exercise regimen designed to promote weight loss. 11 While it is not well understood why patients with diabetes find it harder to achieve weight loss, a number of factors may confound attempts to reduce body weight in this population:
Patients with type 2 diabetes are typically older and may have comorbidities affecting their body weight. The programme of diet and exercise prescribed in diabetes is often designed primarily to achieve good glycaemic control rather than to achieve maximum weight loss. Patients with type 2 diabetes may be the recipients of a number of therapies for the management of diabetes and other coexisting clinical conditions -therapies that may enhance body weight or limit weight loss. For example, the sulphonylureas and insulin, used in the management of diabetes, promote weight gain. Patients with diabetes may have made many previous attempts to lose weight before they developed diabetes, thereby reducing their success in further attempts, as was shown recently by the results of the UKPDS trial. 12 The goal of weight reduction remains important for patients with diabetes, however, and, despite the fact that weight loss is harder to achieve for these patients, the benefits of weight reduction can be clinically very meaningful.
Advantages of weight loss in diabetic patients
It is well known that moderate weight reduction may lead to an important risk reduction from 10% (blood pressure) to up to 30 -35% for triglycerides and haemostatic parameters. 13, 14 A modest weight loss of 5 -10% of body weight is clinically important in patients with type 2 diabetes and can be shown to induce advantageous changes in markers of risk, eg HbA 1c (see Figure 2) .
Glycaemic control and insulin sensitivity are improved, lipid abnormalities are improved and the risk of long-term Treatment of obesity with sibutramine LF Van Gaal and FW Peiffer complications is reduced by the metabolic improvements that accompany a fall in weight. In patients who achieved a mean weight loss of 9.9 kg in 1 y, significant changes were seen from baseline in:
HbA 1c levels, as indicator of long-term glycaemic control (71.1%; P < 0.001); fasting blood glucose (71.6 mmol=l; P < 0.05); triglycerides (70.5 mmol=l; P < 0.01); high-density lipoprotein C (HDL-C)( þ 0.1 mmol=l; P < 0.05).
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The landmark UK Prospective Diabetes Study (UKPDS) of type 2 diabetes and its management has shown that changes which induce a 1% reduction in HbA 1c have a major impact in reducing the risks associated with diabetes. 12 This apparently modest reduction in HbA 1c reflects a: 21% reduction in risk in all diabetes-related complications; 25% reduction in diabetes mortality; 17% reduction in total mortality; 18% reduction in acute myocardial infarction; 35% reduction in risk for microangiopathy.
A 10% weight loss also increases life expectancy in patients with type 2 diabetes. Studies by Williamson et al and Lean et al suggest that this degree of weight loss reduces all-cause mortality in diabetic patients by 20% and diabetes-associated mortality by 30%. 15, 16 Life expectancy increases in proportion to the magnitude of weight loss in the obese diabetic population, 16 suggesting that early and sustained weight loss is vital to improve the prognosis in these patients (see Figure 3 ).
Sibutramine in type 2 diabetes
Sibutramine is the first of a new generation of weight management drugs, and offers improved long-term control of weight when used as an adjunct to diet and exercise. The efficacy of sibutramine for weight loss in obese patients with diabetes has been investigated in a number of controlled clinical studies. A meta-analysis of data from three such studies shows that three times as many sibutramine-treated patients achieved 5% and 10% weight loss compared with controls. 17 Figure 4 shows a new meta-analysis of these data. Over 50% of the diabetes patients receiving daily sibutramine achieved > 5% loss of weight, and of these over 20% achieved > 10% weight loss.
The three weight management studies in diabetes involved in the meta-analysis assessed: sibutramine with diet alone (a 12 month study), sibutramine in a sulphonylurea-treated cohort (a 6 month study), sibutramine in metformin-treated patients (a 12 month study).
Irrespective of the diabetes management programme prescribed to improve glycaemic control, sibutramine therapy improved weight loss compared with diabetic control programmes alone.
For many of the patients studied with type 2 diabetes, sibutramine was used at a daily dose of 15 mg. This dose is higher than that usually used as start-up treatment for nondiabetic obese patients, and was chosen in an attempt to overcome the known difficulties of promoting and inducing weight loss in type 2 diabetes.
The effects of sibutramine on waist circumference -an indicator of visceral fat -have also been assessed in the diabetic population. Patients with type 2 diabetes typically have at least 20 -25% more visceral fat than non-diabetic patients. Daily treatment with 15 mg of sibutramine signifi- Treatment of obesity with sibutramine LF Van Gaal and FW Peiffer cantly reduced waist circumference compared with antidiabetic treatment alone. 17 The weight reduction associated with sibutramine therapy is also accompanied by changes in HbA 1c levels. Analysis of the three studies in type 2 diabetic patients shows that in the subgroup that achieved > 10% reduction in body weight with sibutramine therapy ( > 20% of subjects), there were clinically significant (P < 0.01) reductions in HbA 1c . 17 The improvement in HbA 1c level was proportional to weight loss.
Weight management with sibutramine confers additional benefits for the patient with type 2 diabetes. Treatment improves the lipid profile of the diabetic, raising HDL-C and reducing triglycerides (see Figure 5 ). 17 
Predicting responses
In non-diabetic obese patients, after 1 month on sibutramine therapy it is often possible to predict which patients are going to respond well to this adjunct therapy. Patients with type 2 diabetes are slow to lose weight; nevertheless, our analyses of the three diabetic studies show that even patients who are not achieving 1 kg weight loss at 1 month can still enjoy clinically important weight loss after 1 y on sibutramine treatment. Even after 3 months on therapy, an obese patient with diabetes who appears to be a slow responder may after 1 y has managed clinically significant weight loss. For the patient with type 2 diabetes, a reduction in waist circumference of 10% or more can result in a fall in HbA 1c of 1.3% -a value that is important in achieving the diabetes management goal of improved glycaemic control. Thus, the same predictive value should not be placed on weight loss progress at 1 month and 3 months as would be given nondiabetic overweight patients, and it is important to persist in the diabetic patient with efforts to specify dietary change, increased physical activity and changes in behavioural patterns.
Other aspects of the assessment and monitoring of sibutramine therapy for diabetic patients do not differ greatly from those advised in otherwise healthy obese patients.
Sibutramine is well tolerated in diabetic patients and its use should be accompanied by the same monitoring of vital signs in this population as are advised in the nondiabetic population.
Summary
Pharmacotherapy, sibutramine in particular, can play a role before the onset of diabetes, in controlling excessive weight gain which is a known risk factor for the development of type 2 diabetes. In overweight patients with clinically diagnosed type 2 diabetes, sibutramine is a valuable aid to weight reduction. By increasing the rate and extent of weight loss, sibutramine can improve glycaemic control and help to normalise the metabolic abnormalities associated with type 2 diabetes. In so doing, sibutramine can improve the prognosis for many patients. The report by Lauterbach and Evers suggests that a weight management programme with sibutramine in patients with type 2 diabetes can be associated with weight loss induced benefits in cardiovascular disease risk factors, significantly improving the clinical outlook for this increasing population of patients. 18 As part of the overall management of the obese population and in managing diabetic patients, sibutramine can help in disease prevention, can delay disease progression and may be a useful tool in the prevention and management of diabetic complications.
Conservative estimates made by the Organisation for Economic Co-operation and Development (OECD) 19 indicate that there could also be considerable economic benefits to the management of obesity in diabetes.
